Skip to main content
. 2022 May 19;20:237. doi: 10.1186/s12951-022-01456-z

Fig. 3.

Fig. 3

The affinity test of C44-Fc with human and mouse ANGPTL3 proteins. a Diagram of the C44 fused with human IgG1 Fc fragments. b The SDS-PAGE analysis of the C44-Fc. M: Maker; lane 1: SDS-PAGE analysis of C44-Fc in reduced gel; lane 2: SDS-PAGE analysis of C44-Fc in non-reduced gel. c, g and k The affinity of C44-His6, C44-Fc and evinacumab binding to hANGPTL3 (S17-E460)-His10. d, h and l The affinity of C44-His6, C44-Fc and evinacumab binding to mANGPTL3 (S17-T206)-His6. e, i and m The affinity of C44-His6, C44-Fc and evinacumab binding to mANGPTL3 (S17-T455)-His10. f and j The affinity of C44-Fc and evinacumab binding to hANGPTL3 (S17-P220)-His6